menu
    • menu
    [{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WPD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Worldwide Clinical Trials"}]

    Find Clinical Drug Pipeline Developments & Deals for Berubicin

    Menu

    Berubicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CNS Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CNS Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berubicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

                            Details : Berubicin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 21, 2021

                            Lead Product(s) : Berubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            WPD Pharmaceuticals

                            Poland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WPD Pharmaceuticals

                            Poland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berubicin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            WPD Pharma to Conduct Clinical Trials in Pediatric Brain Tumors

                            Details : The Company, in collaboration with CNS, is planning to conduct the upcoming Phase I clinical trial at Children's Memorial Health Institute

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 12, 2020

                            Lead Product(s) : Berubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth